| | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
---|
|
L | | IP | | | Lutrelef 3,2 mg | Durchstechflasche(n) | 300.71 | 343.45 | 10 % | | Injection preparation: Gonadorelini Acetas 3.2 mg | Ferring AG | B / SL | FB | | G |  |
|
| | IP | CI | | Stilamin 3 mg | | PR | PR | k.A. | | Lyophilisate: Somatostatinum 3 mg | Hasten Biopharmaceutic (Switzerland) AG | A | FB | | G |  |
| | IP | CI | | Stilamin 3 mg | ampoule(s) | PR | PR | k.A. | | Lyophilisate: Somatostatinum 3 mg | Hasten Biopharmaceutic (Switzerland) AG | A | FB | | G |  |
|
L | | IP | CI | | Sandostatin 0,05 mg/mL | 5 1 ampoule(s) à 1 ml | 22.19 | 40.40 | 10 % | | Injection solution: Octreotidum | Novartis Pharma Schweiz AG | A / SL / SO | FB | | G |  |
L | | IP | CI | | Sandostatin 0,1 mg/mL | 5 1 ampoule(s) à 1 ml | 41.38 | 61.15 | 10 % | | Injection solution: Octreotidum | Novartis Pharma Schweiz AG | A / SL / SO | FB | | G |  |
L | | IP | CI | | Sandostatin 0,5 mg/mL | 5 1 ampoule(s) à 1 ml | 227.65 | 262.60 | 10 % | | Injection solution: Octreotidum | Novartis Pharma Schweiz AG | A / SL / SO | FB | | G |  |
L | | IP | CI | | Sandostatin LAR 10 mg Fertigspritzen | 10 mg | 505.79 | 560.55 | 10 % | | Injection preparation: Octreotidum 10 mg | Novartis Pharma Schweiz AG | A / SL / SO | FB | | G |  |
L | | IP | CI | | Sandostatin LAR 20 mg Fertigspritzen | 20 mg | 897.90 | 982.40 | 10 % | | Injection preparation: Octreotidum 20 mg | Novartis Pharma Schweiz AG | A / SL / SO | FB | | G |  |
L | | IP | CI | | Sandostatin LAR 30 mg Fertigspritzen | 30 mg | 1265.46 | 1377.85 | 10 % | | Injection preparation: Octreotidum 30 mg | Novartis Pharma Schweiz AG | A / SL / SO | FB | | G |  |
L | | IP | | | Octreotid Labatec 0,05 mg/mL | 5 1 ampoule(s) à 1 ml | 19.99 | 38.15 | 10 % | | Solution pour injection: Octreotidum | Labatec Pharma SA | A / SL / SG | FB | | G |  |
L | | IP | | | Octreotid Labatec 0,1 mg/mL | 5 1 ampoule(s) à 1 ml | 37.24 | 56.90 | 10 % | | Solution pour injection: Octreotidum | Labatec Pharma SA | A / SL / SG | FB | | G |  |
L | | IP | | | Octreotid Labatec 0.2 mg/ml | Durchstechflasche(n) à 5 ml | 69.54 | 92.05 | 10 % | | Solution pour injection: Octreotidum 1mg / 5ml | Labatec Pharma SA | A / SL / SG | FB | | G |  |
L | | IP | | | Octreotid Labatec 0,5 mg/mL | 5 1 ampoule(s) à 1 ml | 204.98 | 239.35 | 10 % | | Solution pour injection: Octreotidum | Labatec Pharma SA | A / SL / SG | FB | | G |  |
| | IP | | | Octreotid-Teva 0.05 mg/ml | Durchstechflasche(n) | PR | PR | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | | G |  |
| | IP | | | Octreotid-Teva 0.05 mg/ml | 5 Durchstechflasche(n) | PR | PR | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | | G |  |
| | IP | | | Octreotid-Teva 0.1 mg/ml | Durchstechflasche(n) | PR | PR | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | | G |  |
| | IP | | | Octreotid-Teva 0.1 mg/ml | 5 Durchstechflasche(n) | PR | PR | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | | G |  |
| | IP | | | Octreotid-Teva 0.2 mg/ml | Durchstechflasche(n) | PR | PR | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | | G |  |
| | IP | | | Octreotid-Teva 0.5 mg/ml | Durchstechflasche(n) | PR | PR | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | | G |  |
| | IP | | | Octreotid-Teva 0.5 mg/ml | 5 Durchstechflasche(n) | PR | PR | k.A. | | Injektionslösung oder Konzentrat zur Herstellung einer Infusionslösung: Octreotidum | Teva Pharma AG | A | FB | | G |  |
|
L | | IP | CI | | Somatuline Autogel 60 mg | | 725.83 | 805.80 | 10 % | | Injection solution: Lanreotidum 60 mg | Ipsen Pharma Schweiz GmbH | A / SL | FB | | G |  |
L | | IP | CI | | Somatuline Autogel 90 mg | | 1001.92 | 1106.05 | 10 % | | Injection solution: Lanreotidum 90 mg | Ipsen Pharma Schweiz GmbH | A / SL | FB | | G |  |
L | | IP | CI | | Somatuline Autogel 120 mg | | 1290.70 | 1420.15 | 10 % | | Injection solution: Lanreotidum 120 mg | Ipsen Pharma Schweiz GmbH | A / SL | FB | | G |  |
|
L | | IP | CI | PP | Signifor 0.3 mg/1 ml | 30 ampoule(s) | 2013.84 | 2206.60 | 10 % | | Injection solution: Pasireotidum | Recordati AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Signifor 0.6 mg/1 ml | 30 ampoule(s) | 2013.84 | 2206.60 | 10 % | | Injection solution: Pasireotidum | Recordati AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Signifor 0.9 mg/1 ml | 30 ampoule(s) | 2013.84 | 2206.60 | 10 % | | Injection solution: Pasireotidum | Recordati AG | B / SL | FB | | G |  |
L | | IP | CI | PP | Signifor LAR 20 mg | Durchstechflasche(n) à 20 mg | 3011.01 | 3291.05 | 10 % | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 20 mg | Recordati AG | A / SL | FB | | G |  |
L | | IP | CI | PP | Signifor LAR 40 mg | Durchstechflasche(n) à 40 mg | 3011.01 | 3291.05 | 10 % | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 40 mg | Recordati AG | A / SL | FB | | G |  |
L | | IP | CI | PP | Signifor LAR 60 mg | Durchstechflasche(n) à 60 mg | 3011.01 | 3291.05 | 10 % | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 60 mg | Recordati AG | A / SL | FB | | G |  |
| | IP | | PP | Signifor LAR 10 mg | 10 mg | PR | PR | k.A. | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 10 mg | Recordati AG | A | FB | | G |  |
| | IP | | PP | Signifor LAR 30 mg | 30 mg | PR | PR | k.A. | | Pulver und Lösung zur Herstellung einer Injektionssuspension: Pasireotidum 30 mg | Recordati AG | A | FB | | G |  |
|
| | IP | CI | | Orgalutran | | PR | PR | k.A. | | Injection solution: Ganirelixum | Organon GmbH | A | FB | | G |  |
| | IP | CI | | Orgalutran | 5 syringe(s) | PR | PR | k.A. | | Injection solution: Ganirelixum | Organon GmbH | A | FB | | G |  |
| | IP | CI | | Ovamex | | PR | PR | k.A. | | Injection solution in prefilled syringe: Ganirelixum | Future Health Pharma GmbH | A | FB | | G |  |
| | IP | CI | | Ovamex | 5 | PR | PR | k.A. | | Injection solution in prefilled syringe: Ganirelixum | Future Health Pharma GmbH | A | FB | | G |  |
| | IP | CI | | Ganirelix Labatec 0,25 mg | | PR | PR | k.A. | | solution injectable en seringue préremplie: Ganirelixum | Labatec Pharma SA | A | FB | | G |  |
| | IP | CI | | Ganirelix Labatec 0,25 mg | 5 | PR | PR | k.A. | | solution injectable en seringue préremplie: Ganirelixum | Labatec Pharma SA | A | FB | | G |  |
|
| SIP | IP | CI | | Cetrotide 0,25 mg | Durchstechflasche(n) | PR | PR | k.A. | | | Merck (Schweiz) AG | A | FB | | G |  |
|
| | IP | CI | | Ryeqo | 28 | PR | PR | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter (Schweiz) AG | B | FB | | G |  |
| | IP | CI | | Ryeqo | 84 | PR | PR | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter (Schweiz) AG | B | FB | | G |  |
| | IP | CI | | Ryeqo | 28 | PR | PR | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter (Schweiz) AG | B | FB | | G |  |
| | IP | CI | | Ryeqo | 84 | PR | PR | k.A. | | Coated tablets: 3 Active Agents | Gedeon Richter (Schweiz) AG | B | FB | | G |  |